Mark J. Zucker

Mark J. Zucker

Transplant Surgery | Cardiology
1A Regulus Drive
Turnersville, NJ 08012

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Is It the Nature of the Challenge or the Lack of Nurture? The Value of FDA Support and Public-Private Partnerships in Mechanical Circulatory Support.

Is It the Nature of the Challenge or the Lack of Nurture? The Value of FDA Support and Public-Private Partnerships in Mechanical Circulatory Support.

Journal: Artificial organs
Published: April 28, 2025

Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer.

Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer.

Journal: Nature genetics
Published: November 08, 2024

HeartMate 3 left ventricular assist device infection-related left ventricular pseudoaneurysm: Extirpation in the setting of left ventricular recovery.

HeartMate 3 left ventricular assist device infection-related left ventricular pseudoaneurysm: Extirpation in the setting of left ventricular recovery.

Journal: JTCVS techniques
Published: October 03, 2024

Surgical Outcomes and Genomic Insights of Nonclear Cell Renal Cell Carcinoma With Synchronous and Metachronous Nodal Disease.

Surgical Outcomes and Genomic Insights of Nonclear Cell Renal Cell Carcinoma With Synchronous and Metachronous Nodal Disease.

Journal: Urology practice
Published: June 24, 2024

Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer.

Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer.

Journal: Cell
Published: November 03, 2023

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.

Journal: European urology oncology
Published: May 21, 2023

Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.

Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.

Journal: Frontiers in oncology
Published: March 31, 2022

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 17, 2022

A new flow cytometry assay identifies recipient IgG subtype antibodies binding donor cells: increasing donor availability for highly sensitised patients.

A new flow cytometry assay identifies recipient IgG subtype antibodies binding donor cells: increasing donor availability for highly sensitised patients.

Journal: Clinical & translational immunology
Published: December 08, 2021

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.

Journal: European urology focus
Published: October 27, 2021

Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.

Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.

Journal: Genome research
Published: June 20, 2021

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 09, 2020
Showing 1-12 of 46

Last Updated: 09/26/2026